Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shionogi & Co ( (JP:4507) ) has shared an update.
Shionogi & Co., Ltd. reported its consolidated financial results for the fiscal year 2024, showing a slight increase in revenue and operating profit compared to the previous year. The company conducted a 3-for-1 stock split effective October 2024, which impacted earnings per share calculations. Despite a decline in comprehensive income, the company forecasts significant growth in revenue and profit for the fiscal year ending March 2026, indicating a positive outlook for stakeholders.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company listed on the Tokyo Stock Exchange, primarily focused on the research, development, and marketing of medicines. The company is known for its work in infectious diseases and central nervous system disorders, with a notable market presence in these areas.
YTD Price Performance: 9.76%
Average Trading Volume: 2,564,400
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen2115.7B
Learn more about 4507 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue